Photocure ASA
OSE:PHO

Watchlist Manager
Photocure ASA Logo
Photocure ASA
OSE:PHO
Watchlist
Price: 59 NOK 0.51% Market Closed
Market Cap: 1.6B NOK
Have any thoughts about
Photocure ASA?
Write Note

Operating Margin
Photocure ASA

7.9%
Current
-2%
Average
6.8%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
7.9%
=
Operating Profit
41.7m
/
Revenue
526.3m

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
NO
Photocure ASA
OSE:PHO
1.6B NOK
8%
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY
-83%
US
Eli Lilly and Co
NYSE:LLY
747.7B USD
35%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
3%
DK
Novo Nordisk A/S
CSE:NOVO B
2.8T DKK
44%
US
Johnson & Johnson
NYSE:JNJ
342.5B USD
28%
US
Merck & Co Inc
NYSE:MRK
252.8B USD
34%
CH
Roche Holding AG
SIX:ROG
216.7B CHF
32%
UK
AstraZeneca PLC
LSE:AZN
170.3B GBP
21%
CH
Novartis AG
SIX:NOVN
179.3B CHF
31%
US
Pfizer Inc
NYSE:PFE
152.2B USD
22%
Country NO
Market Cap 1.6B NOK
Operating Margin
8%
Country JP
Market Cap 776 550.9T JPY
Operating Margin
-83%
Country US
Market Cap 747.7B USD
Operating Margin
35%
Country UK
Market Cap 440.4B GBP
Operating Margin
3%
Country DK
Market Cap 2.8T DKK
Operating Margin
44%
Country US
Market Cap 342.5B USD
Operating Margin
28%
Country US
Market Cap 252.8B USD
Operating Margin
34%
Country CH
Market Cap 216.7B CHF
Operating Margin
32%
Country UK
Market Cap 170.3B GBP
Operating Margin
21%
Country CH
Market Cap 179.3B CHF
Operating Margin
31%
Country US
Market Cap 152.2B USD
Operating Margin
22%
No Stocks Found

Photocure ASA
Glance View

Market Cap
1.6B NOK
Industry
Pharmaceuticals

Photocure ASA delivers transformative solutions to improve the lives of bladder cancer patients. The company is headquartered in Oslo, Oslo. The company went IPO on 2000-05-29. The company operates in the field of photodynamic diagnosis, cosmetics and treatment of acne, bladder cancer, colon cancer, as well as human papilloma virus (HPV) and precancerous lesions of the cervix. The Company’s activities comprise research, development and commercialization of pipeline projects within two segments: Cancer and Dermatology. Its brand portfolio includes: Hexvix and Cysview, for detection and management of bladder cancer; Visonac, for acne treatment; Cevira, used in HPV and precancerous lesions of the cervix treatment; and Lumacan, applied in colorectal cancer treatment. Furthermore, It owns a Photocure Technology platform, which develops photodynamic technology for diagnosis and therapy. The firm is a parent of a wholly owned entity, Photocure Inc.

PHO Intrinsic Value
88.89 NOK
Undervaluation 34%
Intrinsic Value
Price
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
7.9%
=
Operating Profit
41.7m
/
Revenue
526.3m
What is the Operating Margin of Photocure ASA?

Based on Photocure ASA's most recent financial statements, the company has Operating Margin of 7.9%.